Does MYRIAD GENETICS, INC. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores MYRIAD GENETICS, INC. (MYGN) 46.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 94, returns on capital 7, balance-sheet safety 55, capital discipline 24.

How has MYGN's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 46.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

MYRIAD GENETICS, INC.

MYGN · Healthcare · $577.8M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power94

Median gross margin 70.1% over 6y, stable.

Returns on capital7

Median ROIC -14.3%, above the 9% hurdle in 20% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $6.18
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for MYGN yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale46.2 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — MYGN has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#153 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#151PTPI Petros Pharmaceuticals, Inc.46.3 out of 100, Shallow moatShallow moat
#152DAIO Data I/O Corporation46.2 out of 100, Shallow moatShallow moat
#154XFOR X4 Pharmaceuticals, Inc.46.2 out of 100, Shallow moatShallow moat
#155CYH COMMUNITY HEALTH SYSTEMS, INC.46.0 out of 100, Shallow moatShallow moat

Compare MYGN with its nearest peers →All Healthcare companies on the Index →

Common questions about MYGN

Does MYRIAD GENETICS, INC. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores MYRIAD GENETICS, INC. (MYGN) 46.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 94, returns on capital 7, balance-sheet safety 55, capital discipline 24.
How has MYGN's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 46.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows MYGN’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/MYGN"
  width="340" height="150" style="border:0"
  title="MYGN Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell MYGN. See the disclaimer.